ArticleClinical and translational radiation oncology2023

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.

Maximilien Rogé et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.